Review Article
Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies
Table 3
Induced models of B-cell lymphoma. (m): murine origin; (h): human origin; (i): syngeneic models; (ii): syngeneic models with murine tumor cells engineered to express human antigens; (iii): xenogenic models; (iv): humanized models; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; MALT: mucosa associated lymphatic tissue; n.d.: not determined; PCL: primary cerebral lymphoma; PCNSL: primary central nervous system lymphoma; PIOL: primary intraocular lymphoma; SCID: severe combined immune deficiency.
| | Injection site | Name | Lymphoma model | Recipient mice | Major reference | | Strain (haplotype) | MHC compatibility | Immune status |
| | Intravenous | B6 spontaneous model (m) | High-grade B lymphoma | C57Bl/6 (H-2b) | Syngeneic (i) | Immunocompetent | [51] | | Pi-BCL1 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [52] | | 38C13 (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (i) | Immunocompetent | [53] | | FL5.12 transfected by Bcl2 (m) | Non-Hodgkin lymphoma | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [42] | | A20 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [54] | | 4TOO (m) | n.d. | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [55] | | BCL1 (m) | CLL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [56] | | 38C13 Her2/neu (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [40] | | Z138 (h) | Human mantle cell lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [57] | | BJAB (h) | Burkitt lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | | SU-DHL-4 (h) | DLBCL | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [59] |
| | Intrasplenic | A20 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [60] | | A20.IIA-GFP (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [50] |
| | Intraperitoneal | CH44 (m) | Non-Hodgkin lymphoma | B10.H-2aH-4bp/Wts | Syngeneic (i) | Immunocompetent | [34] | | BCL1 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [53] | | 38C13 (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (i) | Immunocompetent | [53] | | Tonsillar lymphocytes and EBV infection (h) | Viro-induced lymphoma | BNXhum (humanized) | Allogenic (iv) | Immunocompetent | [61] |
| | Subcutaneous | LY-ar or LY-as (m) | n.d. | C3Hf/kam (H-2k) | Syngeneic (i) | Immunocompetent | [37] | | S11 (m) | Burkitt lymphoma | BALB/c nude (H-2d) | Syngeneic (i) | T-cell deficiency | [62] | | LMycSN-p53null (m) | Non-Hodgkin lymphoma | C57Bl/6 (H-2b) | Syngeneic (i) | Immunocompetent | [18] | | A20 (m) | DLBCL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [63] | | 38C13 Her2/neu (m) | Non-Hodgkin lymphoma | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [40] | | Myc5-M5 (m) | n.d. | SCID mice (H-2d) | Allogenic | Immunodeficient | [17] | | Splenic Hodgkin lymphoma cells (h) | Hodgkin disease | Nude mice (H-2b) | Xenogenic (iii) | T-cell deficiency | [64] | | Human hodgkin cell line (h) | Hodgkin disease | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [47] | | Ramos (h) | Burkitt lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | | BJAB (h) | Burkitt lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | | SC-1 (h) | Follicular lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | | DoHH-2 (h) | Follicular lymphoma | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [58] | | SuDHL-4 (h) | DLBCL | C.B-17 SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [65] | | Granta 519 (h) | Mantle cell lymphoma | C.B-17 SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [65] | | HKBML (h) | Brain DLBCL | C.B-17 SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [46] | | Daudi (h) | Burkitt lymphoma | SCID/beige mice (H-2d) | Xenogenic (iv) | Partially rebuilt | [66] | | Jijoye (h) | Burkitt lymphoma | SCID/beige mice (H-2d) | Xenogenic (iv) | Partially rebuilt | [66] |
| | Intramuscular | MSV-MuLV-M induced | Waldenstrom's macroglobulinemia | C57Bl/6 (H-2b) | Syngeneic | Immunocompetent | [67] | | Mouse lymphosarcoma cell line (m) | Non-Hodgkin lymphosarcoma | CBA (H-2k) | Syngeneic (i) | Immunocompetent | [41] |
| | Stomach | Helicobacter felis | MALT lymphoma | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [48] |
| | Intracerebral | A20.IIA-GFP (m) | PCL (PCNSL) | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [50] | | 38C13 CD20+ (m) | PCL (PCNSL) | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [68] | | Raji (h) | PCL (PCNSL) | Nude mice (H-2b) | Xenogenic (iii) | T-cell deficiency | [69] | | Patient's cells (h) | PCL (PCNSL) | Nude mice (H-2b) | Xenogenic (iii) | T-cell deficiency | [70] | | MC116 (h) | PCL (PCNSL) | Nude rats (RT1u) | Xenogenic (iii) | Immunodeficient | [71] |
| | Cisterna magna | L1210 (m) | Leptomeningeal metastases | DBA/2 (H-2d) | Syngeneic (i) | Immunocompetent | [72] |
| | Intraocular | A20.IIA-GFP (m) | PIOL | BALB/c (H-2d) | Syngeneic (i) | Immunocompetent | [45] | | 38C13 CD20+ (m) | PIOL | C3H/HeN (H-2k) | Syngeneic (ii) | Immunocompetent | [68] | | CA46 (h) | PIOL | SCID mice (H-2d) | Xenogenic (iii) | Immunodeficient | [73] |
|
|
